Basic Information
| Clone | Abatacept Biosimilar |
|---|
| Endotoxin | <1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay |
|---|
| Sterility | 0.2 μm filtration |
|---|
| Aggregation | <5% Determined by SECP |
|---|
| Purity | >95% Determined by SDS-PAGE |
|---|
Product Information
| Production | Purified from cell culture supernatant in an animal-free facility |
|---|
| Purification | Protein A or G purification |
|---|
| Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
|---|
Target Background
Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.
Immunogen Information
| Isotype | Human IgG1 Fc |
|---|
| Immunogen | / |
|---|
| RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Fc Protein |
|---|
| Recommended Dilution Buffer | 1×PBS pH 7.0 |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
A1_FC_01.jpg?t=1702607073)
